Covidien Pays Medrad $17M, Ending Multiple Suits
Covidien revealed in a filing with the U.S. Securities and Exchange Commission on Monday that Medrad has agreed to drop its patent infringement claims while Covidien has dropped its claims that the asserted patents were invalid and not infringed. The parties filed stipulations to dismiss two lawsuits with prejudice on Monday.
Also as part of the deal reached on Jan. 18, another...
To view the full article, register now.